BXRX Baudax Bio Inc - Ordinary Shares

8.3
-0.15  -2%
Previous Close 8.46
Open 8.61
Price To Book -2.19
Market Cap 77,657,638
Shares 9,350,709
Volume 125,026
Short Ratio
Av. Daily Volume 168,141
Stock charts supplied by TradingView

NewsSee all news

  1. Baudax Bio Announces PDUFA Date for Intravenous Meloxicam

    MALVERN, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug

  2. Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference

    MALVERN, Pa., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Baudax Bio, Inc., (NASDAQ:BXRX) a pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

First CRL announced May 24, 2018. Second CRL issued March 22, 2019. New PDUFA date February 20, 2020
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery
Phase 1 trial to be initiated 1H 2020.
RP-1000

Latest News

  1. Baudax Bio Announces PDUFA Date for Intravenous Meloxicam

    MALVERN, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug

  2. Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference

    MALVERN, Pa., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Baudax Bio, Inc., (NASDAQ:BXRX) a pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings,